<DOC>
	<DOC>NCT02119793</DOC>
	<brief_summary>This study is purposed to evaluate the long-term efficacy and safety of repeat treatment of YVOIRE® contour injected into the anteromedial malar region in subjects who have completed the LG-HACL014 study.</brief_summary>
	<brief_title>Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE® Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study</brief_title>
	<detailed_description />
	<criteria>Eligible subjects who have completed the LGHACL014 study Have anteromedial malar region volume loss at least a onepoint worse on the MFAS compared with 2 weeks after treatment in the LGHACL014 study Accept the obligation not to receive any other mid facial procedures or treatments during the study Signed informed consent Those who fall under one of the following 3 cases 1. Males or females who are surgically sterile 2. PostMenopausal females who are above 45 years of age and 2 years after the last menstruation 3. Fertile premenopausal females or males without having a surgical sterilization, who have agreed to use at least two contraception methods (one of the barrier methods must be included) for up to 14 days after the repeat treatment of the investigational device to avoid pregnancy Have a history of hypertrophic scars or keloids Other criteria as identified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>